share_log

Investors Shouldn't Be Too Comfortable With Youngy Health's (SZSE:300247) Earnings

Investors Shouldn't Be Too Comfortable With Youngy Health's (SZSE:300247) Earnings

投资者不应该对融捷健康(SZSE:300247)的盈利过于放心
Simply Wall St ·  2024/09/05 07:16

Despite posting some strong earnings, the market for Youngy Health Co., Ltd.'s (SZSE:300247) stock hasn't moved much. Our analysis suggests that shareholders have noticed something concerning in the numbers.

尽管融捷健康有限公司(SZSE:300247)发布了一些强劲的收益,但股票市场并没有出现太大波动。我们的分析表明,股东们已经注意到数字中的一些令人担忧的地方。

big
SZSE:300247 Earnings and Revenue History September 4th 2024
SZSE:300247营收和利润历史数据2024年9月4日

The Impact Of Unusual Items On Profit

除了稀释之外,还应该注意的是,万集科技在过去12个月中因不寻常项目获得了价值人民币3.5万元的利润。虽然我们希望看到利润增加,但当这些不寻常项目对利润做出重大贡献时,我们会更加谨慎。我们对全球大部分上市公司的数据进行了分析,发现不寻常项目往往是一次性的。这正如我们所期望的那样,因为这些提升被描述为"不寻常"。相对于其利润而言,万集科技在2021年12月前的不寻常项目贡献大。因此,我们可以推断出,这些不寻常项目正在使其财务利润显著增强。

To properly understand Youngy Health's profit results, we need to consider the CN¥16m gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. We can see that Youngy Health's positive unusual items were quite significant relative to its profit in the year to June 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

为了正确理解融捷健康的利润结果,我们需要考虑到归因于飞凡项目的1600万人民币收益。虽然利润增加总是令人愉悦的,但来自飞凡项目的巨额贡献有时会减弱我们的热情。当我们分析了全球大多数上市公司时,发现重要的飞凡项目通常不会重复出现。这符合预期,因为这些提振被描述为“飞凡”。我们可以看到,融捷健康在2024年6月的年度利润中,来自飞凡项目的正面影响相当显著。其他条件相同的情况下,这可能会导致法定利润成为衡量基本盈利能力的一个不良指标。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Youngy Health.

注:我们始终建议投资者检查资产负债表的实力。点击这里查看我们对融捷健康的资产负债表分析。

Our Take On Youngy Health's Profit Performance

我们对融捷健康的利润表现的看法

As previously mentioned, Youngy Health's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. For this reason, we think that Youngy Health's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. But the happy news is that, while acknowledging we have to look beyond the statutory numbers, those numbers are still improving, with EPS growing at a very high rate over the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. While conducting our analysis, we found that Youngy Health has 1 warning sign and it would be unwise to ignore it.

正如先前提到的,融捷健康受益于飞凡项目的大幅提升,但这种情况不会永远持续,因此其法定收益可能不是评估其潜在盈利能力的良好指南。因此,我们认为融捷健康的法定利润可能不是公司潜在收益能力的良好指引,并可能使投资者对公司产生过分乐观的印象。但令人高兴的消息是,尽管我们知道必须超越法定数字来思考,这些数字仍在改善,每股收益在过去一年增长速度非常快。本文的目标是评估我们可以多大程度上依赖法定收益来反映公司的潜力,但还有很多要考虑的地方。因此,如果您想更深入地了解这支股票,考虑到它面临的任何风险是至关重要的。在进行分析时,我们发现融捷健康有一个警示信号,如果忽视它将是不明智的。

This note has only looked at a single factor that sheds light on the nature of Youngy Health's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

本文仅着眼于一项能揭示融捷健康利润性质的单一因素。但还有许多其他方法可以形成对公司的看法。例如,许多人认为股东权益回报率高是良好业务经济的指示,而其他人则喜欢“追踪资金”并寻找内部人员在购买的股票。因此,您可能希望查看这些拥有高股东权益回报率的公司自由收集,或者这些拥有高内部所有权的股票清单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发